文献速递血液净化与透析

腹膜透析患者使用胃酸抑制剂的腹膜炎与死亡风险

Peritonitis and Mortality Risks of Gastric Acid Suppressants in Patients Undergoing Peritoneal Dialysis.
PubMed 文献 · Kidney Int Rep · 2026-07-29

该研究采用目标试验模拟方法,基于香港电子健康记录(2006-2019)分析11,693例腹膜透析患者。结果显示,启动质子泵抑制剂(PPI)与腹膜炎(HR 1.53)、全因死亡(HR 1.55)及腹膜炎相关死亡(HR 1.39)风险升高相关;H2受体拮抗剂(H2RA)亦与腹膜炎(HR 1.21)和全因死亡(HR 1.13)风险升高相关。头对头分析中PPI较H2RA全因死亡风险更高(HR 1.38)。

要点

  • 腹膜透析患者启动PPI或H2RA均与腹膜炎及死亡风险增加相关。
  • PPI较H2RA与更高的全因死亡和腹膜炎相关死亡风险相关。
  • 基线风险较高的患者中,胃酸抑制剂的风险升高更明显。

核心结论

  • 腹膜透析患者启动胃酸抑制剂较未启动者腹膜炎和死亡风险增加,且PPI较H2RA死亡风险更高。

研究设计与样本

  • 目标试验模拟研究,使用香港电子健康记录(2006-2019),采用168个月序贯设计、逆概率治疗加权和离散风险回归。
  • 共纳入11,693例个体,240,431人-试验,比较PPI启动者、H2RA启动者和未启动者。

主要发现

  • PPI启动vs未启动:腹膜炎HR 1.53(95%CI 1.31-1.80),全因死亡HR 1.55(95%CI 1.43-1.67),腹膜炎相关死亡HR 1.39(95%CI 1.05-1.58)。
  • H2RA使用:腹膜炎HR 1.21(95%CI 1.08-1.35),全因死亡HR 1.13(95%CI 1.06-1.20)。
  • PPI vs H2RA头对头:腹膜炎风险无显著增加,全因死亡HR 1.38(95%CI 1.23-1.54),腹膜炎相关死亡HR 1.85(95%CI 1.07-3.19)。
  • 异质性分析显示基线风险较高者风险升高更明显。

临床怎么用

  • 腹膜透析患者应谨慎使用胃酸抑制治疗,尤其PPI。
  • 对高基线风险患者,处方胃酸抑制剂时需更严密监测腹膜炎和死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peritonitis is a critical complication in patients undergoing peritoneal dialysis (PD). The association between gastric acid suppressants (GAS), specifically proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs), and peritonitis risk remains controversial, with conflicting evidence regarding their safety. METHODS: We conducted a target trial emulation using Hong Kong electronic health records (2006-2019), applying a 168-month sequential design to minimize immortal time bias. Using inverse probability of treatment weighting and discrete hazards regression, we estimated hazard ratios (HRs) for peritonitis, all-cause mortality, and peritonitis-related mortality among PPI initiators, H2RA initiators, and non-initiators (95% confidence interval [CI] calculated using 500-resample bootstrapping). We also performed a PPI versus H2RA head-to-head comparison and predictive approaches to treatment effect heterogeneity analysis. RESULTS: Among 11,693 individuals (240,431 person-trials), PPI initiation (vs. non-initiation) was associated with higher risks of peritonitis (HR 1.53, 95% CI 1.31-1.80), all-cause mortality (HR 1.55, 95% CI 1.43-1.67), and peritonitis-related mortality (HR 1.39, 95% CI 1.05-1.58). H2RA use was also associated with increased risk of peritonitis (HR 1.21, 95% CI 1.08-1.35) and all-cause mortality risks (HR 1.13, 95% CI 1.06-1.20). Head-to-head analysis showed no significant increase in peritonitis risk with PPIs versus H2RAs, but revealed an association between PPI use and higher all-cause mortality (HR 1.38, 95% CI 1.23-1.54) and peritonitis-related mortality (HR 1.85, 95% CI 1.07-3.19). Predictive approaches to treatment effect heterogeneity analysis indicated that risk elevations were more pronounced in individuals with higher baseline risk. CONCLUSIONS: In patients on PD, GAS initiation is associated with increased peritonitis and mortality compared with non-initiation. Furthermore, PPIs were associated with higher mortality risks than H2RAs. These findings highlight the need for cautious use of acid-suppressive therapy.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Fan M, Man KKC, Li X, et al. Peritonitis and Mortality Risks of Gastric Acid Suppressants in Patients Undergoing Peritoneal Dialysis. Kidney Int Rep. 2026. PMID: 42668645. doi:10.1016/j.ekir.2026.106991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。